Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03215810
Recruitment Status : Active, not recruiting
First Posted : July 12, 2017
Last Update Posted : March 2, 2021
Sponsor:
Collaborators:
Bristol-Myers Squibb
Prometheus Inc.
Stand Up To Cancer
Iovance Biotherapeutics, Inc.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023